PolyXen Technology-Based Candidates

PolyXen - Partnered Drug Delivery Programs

Program Indication Preclinical Phase 1 Phase 2 Phase 3 Partners
SHP656 (PSA Factor VIII) Hemophilia A
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started

PSA-FVIII: SHP656 (BAX 826)- PSA-Recombinant Factor VIII

PSA-recombinant SHP656, (BAX 826) or polysialylated recombinant Factor VIII is being developed by our partner Shire plc for the treatment of hemophilia. SHP656 uses our PolyXen platform technology to conjugate PSA to therapeutic blood-clotting factors. The stated goal of Shire is to introduce an innovative FVIII protein that can significantly prolong the circulating half-life of the FVIII protein, with the objective of providing a once weekly treatment or reaching higher trough activity levels for greater efficacy.

In January 2017, we received a $3 million milestone payment from Shire plc related to Shire's advancing the Phase 1/2a clinical study in hemophilia. Shire is actively managing this program and is responsible for all of the development costs under the terms of our agreement.